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This year, the Lasker Foundation confers its Clinical Medical Research Award on Akira Endo for his 
isolation from fungi of statins, potent inhibitors of cholesterol synthesis in the liver. The introduction 
of statins to clinical practice has markedly reduced morbidity and mortality from atherosclerotic 
cardiovascular disease.Among the most persuasive evidence 
for the value to humanity of the synergy 
between academic biomedical research 
and industrial product development has 
been a 50% decrease in deaths from 
heart attacks and strokes over the past 
30 years in the developed world (Fox et 
al., 2007). Many factors have contributed 
to this decline, but one of the most effec-
tive and the most benign has been the 
introduction to routine clinical practice 
of statins. Statins are a class of small 
molecules that reduce blood levels of 
the form of cholesterol that promotes 
atherosclerotic vascular disease, which 
precedes thrombotic events that cause 
tissue damage and blocking of major 
blood vessels. Thanks to the fundamen-
tal discoveries of Akira Endo, this year’s 
winner of the Lasker-DeBakey Award for 
Clinical Medical Research, 14 clinical 
trials involving 91,000 patients with ath-
erosclerotic cardiovascular disease have 
documented a 30% reduction in heart 
attacks after treatment with statins. Fur-
thermore, millions of individuals using 
statins for primary prevention may have 
avoided heart attacks altogether (Stein-
berg, 2007).
Akira Endo was born in November, 
1933 to a farming family in Hagishiyuri, 
Honshu Island, Japan. Following comple-
tion of his degree training at the School 
of Agriculture at Tokohu University, he 
went to work for the Sankyo pharma-
ceutical company in Tokyo. His early 
research at Sankyo was, like Pasteur’s, 
relevant to the beverage industry, and 
he identified a new enzyme for remov-
ing pectins that contaminate wines and 
ciders. This accomplishment was com-
mercially useful to Sankyo, and the com-
pany rewarded Endo with a sabbatical to study phospholipid metabolism in the 
laboratory of Bernard Horecker at Albert 
Einstein Medical College in New York.
Upon returning to his research position 
at Sankyo, Endo embarked on a 2 year 
project to screen 6000 fungal extracts 
for inhibitors of cholesterol biosynthe-
sis, using an assay system in which rat 
liver membranes converted radioactive 
acetate into cholesterol. He identified 
two inhibitory compounds (ML-236A and 
B) that were derived from Penicillium cit-
rinum, a mold that infects the Japanese 
(Mikan) orange (Endo et al., 1976a). In a 
concise publication, Endo reported that 
ML-236B, later renamed compactin or 
mevastatin, is a competitive inhibitor of 
3-hydroxy-3-methylglutaryl coenzyme 
A (HMG CoA) reductase. This enzyme 
regulates the rate-limiting step in cho-
lesterol biosynthesis, and Endo showed 
that ML-236B blocked the activity of 
HMG CoA at nanomolar concentrations 
(Endo et al., 1976b).
In 1976, however, these discoveries 
did not lead on a straightforward path 
to the therapeutic that would redefine 
medical practice. Cholesterol was a 
known constituent of the atheroscle-
rotic plaques lining the walls of blood 
vessels at risk for occlusion. Indeed, 
high blood cholesterol levels had been 
associated with cardiovascular disease 
in epidemiological studies and in animal 
models. But the minimal efficacy of diet 
restriction or administration of the cho-
lesterol-lowering agents available at the 
time contributed to widespread skepti-
cism that influencing blood cholesterol 
could prevent cardiovascular disease. 
The anti-cholesterol medications in use 
had unpleasant side effects, such as 
flushing, gastrointestinal discomfort, Cell 134, Sgallstones, and liver disease, and a puta-
tive cholesterol-lowering drug had earlier 
been taken off the market because it 
caused cataracts. Moreover, the role of 
cholesterol as an essential component 
of cell membranes fostered the staunch 
belief that an effective cholesterol syn-
thesis inhibitor would inevitably lead to 
serious toxicities (Steinberg, 2007).
The teamwork of Michael S. Brown 
and Joseph L. Goldstein at the University 
of Texas Southwestern Medical Center in 
Dallas in the early 1970s began to define 
a clearer picture of cholesterol metabo-
lism that would eventually push back this 
pessimism. An important antecedent to 
their work was the classification of the 
forms in which cholesterol circulates in 
the blood bound to specific lipoproteins 
and the observation that atherosclerotic 
cardiovascular disease incidence cor-
related with high levels of cholesterol-
rich low-density lipoprotein (LDL) (Fre-
drickson et al., 1971). First, Brown and 
Goldstein discovered that patients with 
familial hypercholesterolemia associ-
ated with premature atherosclerosis 
lacked plasma membrane LDL recep-
tors. Then they established the existence 
of a feedback loop in which circulating 
LDL cholesterol negatively regulated 
the quantity of LDL receptors, and they 
demonstrated that the uptake of LDL 
cholesterol via this receptor pathway 
downregulated cholesterol biosynthe-
sis. Patients with familial hypercholes-
terolemia responded to their lack of 
LDL receptors by producing massive 
amounts of cholesterol (Goldstein and 
Brown, 1977). Upon learning serendipi-
tously of Endo’s identification of specific 
and potent cholesterol synthesis inhibi-
tors, Brown and Goldstein asked Endo eptember 19, 2008 ©2008 Elsevier Inc. 903
if they could use them as a key reagent 
to provide additional evidence for their 
metabolic model of cholesterol regula-
tion. Endo generously complied, and the 
Dallas researchers confirmed that com-
pactin inhibited HMG CoA reductase 
activity in fibroblasts from patients with 
familial hypercholesterolemia (Brown et 
al., 1978).
Other investigators showed that 
dietary cholesterol suppressed HMG 
CoA reductase activity in the liver, con-
comitantly lowering plasma levels of 
cholesterol-rich lipoproteins due to 
upregulation of LDL receptors, which 
was consistent with the Brown and 
Goldstein model (Bilheimer et al., 1979). 
Endo documented in rodents that uptake 
of his inhibitory compounds by the liver 
was associated with a reduction in 
cholesterol synthesis that was almost 
exclusively limited to that organ (Endo 
et al., 1977). These results provided 
strong evidence that specific targeting 
of hepatic HMG CoA reductase might be 
a potentially effective and safe strategy 
for controlling blood lipids. Compactin 
did not lower plasma cholesterol levels 
in rodents because most rodent choles-
terol is not in the form of LDL, but it did 
so in chickens, rabbits, and dogs (Endo 
et al., 1979).
In the early 1980s, the encouraging 
results from animal studies were fol-
lowed by a stunning proof-of-concept 
in the clinic. Japanese clinical investiga-
tors using compactin provided by Endo 
obtained the largest reduction ever seen 
in the plasma cholesterol of heterozy-
gous patients with familial hypercho-
lesterolemia (Yamamoto et al., 1980). 
The drug was ineffective in homozygous 
patients because, having no LDL recep-
tor synthesis capacity at all, they could 
not upregulate receptors and scavenge 
LDL, no matter how high the circulating 
LDL cholesterol levels.
Given that Akira Endo is receiving the 
Lasker-DeBakey Award for Clinical Med-
ical Research, it is important to delineate 
how Endo’s pioneering discoveries came 
to be used routinely in medical practice. 
With rare exceptions, only private com-
panies actually develop products that 
physicians use in the clinic. The sta-
tin story, however, belies two common 
misconceptions concerning corporate 
product development: one, that indus-904 Cell 134, September 19, 2008 ©2008 Etry simply expropriates publicly funded 
academic research to make profits, and, 
two, that companies exaggerate the dif-
ficulties and risks of product develop-
ment to inflate product price. Although 
every technology brought to medicine 
by companies has diverse origins, the 
statin example is one of many in which 
private companies have played a major 
role in important product discovery 
as well as development (Zycher et al., 
2008). Indeed, Endo was a pharmaceuti-
cal company employee when he discov-
ered statin compounds and realized their 
clinical potential.
The fact that Endo’s company, San-
kyo, did not bring statins to patients 
and the history of statin development 
at Merck, which did deliver statins to 
the clinic, negate the first misconcep-
tion that trivializes medical product 
development as a formulaic exploita-
tion of basic discoveries. Upon learning 
of Endo’s work, researchers at Merck 
Research Laboratories led by Albert 
Alberts began a screening program for 
HMG CoA reductase inhibitors and iso-
lated the compound eventually named 
lovastatin (Endo independently discov-
ered this compound as well). Merck’s 
development program progressed to 
demonstrating that blood LDL choles-
terol decreases in normal volunteers 
treated with lovastatin with few side 
effects (Tobert et al., 1982). But Merck’s 
work on the project stopped upon learn-
ing that Sankyo had abandoned its statin 
program because of toxicity concerns. 
Large doses of compactin given to dogs 
resulted in gastrointestinal lesions that 
toxicologists interpreted as malignant 
lymphomas. This finding as well as cata-
ract formation in heavily treated animals 
was the basis of Sankyo’s retreat from 
statin development. On the basis of this 
discouraging information the Director 
of Merck Research Laboratories, Roy 
Vagelos, shut down statin development 
as well.
The conservative reaction of both 
companies reflected the uncertainty at 
the time regarding the potential clini-
cal value of cholesterol reduction and 
the pervasive concerns about its pos-
sible toxicity. Even if Endo’s experiments 
demonstrating that statin-mediated inhi-
bition of cholesterol synthesis in animals 
was predominantly located in the liver lsevier Inc.were accurate, they could not rule out 
off-target reactions that might lead to 
untoward side effects.
The statin project lay fallow at Merck for 
3 years until Edward Scolnick assumed a 
leadership role at Merck Research Labo-
ratories. He devoted a significant portion 
of the company’s toxicology budget to 
undertake a comprehensive evaluation 
of lovastatin. The Merck investigators 
gave the drug to various animal species 
alone and together with mevalonate, a 
product of HMG CoA reductase activity. 
After extensive testing, the Merck scien-
tists concluded that the effects observed 
after treatment with lovastatin were due 
to its mechanism of action and not to off-
target or drug-based toxicity. They rea-
soned that the “lymphomas” observed 
in the Sankyo experiments probably 
represented histological changes due 
to subcellular processing of massive 
amounts of drug and were not neoplas-
tic. Armed with the new findings and 
committed to going forward, Scolnick 
encouraged the company to initiate clini-
cal trials to evaluate the LDL cholesterol-
lowering ability and possible side effects 
of lovastatin in humans; the company’s 
extensive toxicity evaluations persuaded 
the US Food and Drug Administration 
(FDA) to permit such testing (Brown and 
Goldstein, 2004). The trial results led to 
FDA approval in 1987, but Merck had to 
stipulate in its product label that no clini-
cal outcome benefit could be inferred 
from those findings—all they could say 
was that statin safely lowered LDL cho-
lesterol levels in blood. Only when the 
results of a landmark clinical trial (4S) 
were unveiled in 1994, revealing that 
lowering of LDL cholesterol significantly 
reduced the recurrence of heart attacks 
(secondary prevention), was the asso-
ciation between cholesterol reduction by 
statins and the inhibition of cardiovas-
cular events established (Scandinavian 
Simvastatin Survival Group, 1994).
Another important enabling factor 
worth mentioning was an NIH-sponsored 
coronary primary heart attack prevention 
trial completed in 1984. This trial dem-
onstrated a 20% decrease in LDL cho-
lesterol and heart attacks in 3806 males 
with high LDL cholesterol treated with 
diet modification and cholestyramine, 
one of the available LDL cholesterol-low-
ering agents (Steinberg, 2007). Although 
the results of this trial did not encourage 
physicians to use the regimen broadly 
because of its limited tolerability, they 
did establish a causal relationship 
between LDL cholesterol reduction and 
cardiovascular clinical benefits. Argu-
ably the trial results encouraged the FDA 
to approve Merck’s lovastatin based on 
the surrogate endpoint of decreased LDL 
cholesterol and encouraged the accrual 
of subjects into the 4S clinical trial.
Endo’s pioneering work and its intro-
duction to the clinic by Merck opened 
the door to further pathophysiological 
and clinical advances. The clear connec-
tion between elevated blood LDL choles-
terol and atherosclerotic complications 
encouraged investigators to study the 
causal links between these phenomena. 
It also encouraged the pharmaceutical 
industry to develop more potent sta-
tins, which have allowed physicians to 
achieve greater LDL cholesterol reduc-
tion and cardiovascular event prevention 
as documented in controlled clinical tri-
als. The results of these advances have 
been a progressive lowering of “nor-
mal” levels of LDL and the spectacular 
improvement in mortality and morbidity 
caused by atherosclerotic complica-
tions. The decreased incidence of fatal or incapacitating heart attacks and strokes 
due to the impact of statins keeps more 
people economically productive and, in 
the short run, saves costs dedicated to 
caring for patients with cardiovascular 
complications.
Statin therapy is not just about living 
longer but about quality of life. Prior to 
the introduction of statins, the drugs 
available to effect modest lowering of 
blood cholesterol had more side effects 
than statins, and low-cholesterol diets 
prescribed by nutritionists were unpalat-
able and tough to follow. Although clini-
cal trials have shown that statins lower 
cholesterol most effectively when com-
bined with dietary modification, a reduc-
tion of LDL cholesterol does not nec-
essarily require abandoning moderate 
enjoyment of gustatory delights.
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